John F. Foley

机构：Rocky Mountain Multiple Sclerosis Clinic · ORCID：0000-0003-0431-7067

发表论文 131 篇 · 总被引 3104 次 · h-index 28

代表论文

• Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing (2019 · Neurology · 被引 200)
• Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022 · The Lancet Neurology · 被引 118)
• Quantitative EEG Biomarkers for Mild Traumatic Brain Injury (2019 · Journal of Clinical Neurophysiology · 被引 81)
• Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing (2019 · Multiple Sclerosis and Related Disorders · 被引 57)
• A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis (2020 · Multiple Sclerosis Journal - Experimental Translational and Clinical · 被引 36)
• The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis (2019 · Multiple Sclerosis and Related Disorders · 被引 35)